Clinical Focus Target physicians and hospital networks treating hypoglycemia due to hyperinsulinism, emphasizing Rezolute's late-stage HI therapy to drive discussions at specialty clinics, rare disease centers, and endocrinology departments.

Strategic Partnerships Leverage recent executive hires and board updates to pursue collaborations with biopharma, payer groups, and patient advocacy coalitions to accelerate market access, value demonstrations, and reimbursement discussions.

Market Readiness Capitalize on ongoing conference participation and investor conference appearances to generate patient referrals, key opinion leader engagement, and broader awareness of RZ358 and related HI therapies.

Value Evidence Highlight the company’s credible funding and revenue backdrop to negotiate favorable pricing, access programs, and milestone-based partnerships with payers and specialty distributors.

Global Access Position for international expansion by identifying opportunities in regions with HI treatment gaps, aligning with value-based contracts, and preparing for potential regulatory harmonization discussions.